Effect of risedronate on hip structural geometry: A 1-year, double-blind trial in chemotherapy-induced postmenopausal women

Bone

Volumn 43, Issue 2, 2008, Pages 274-278

  Van Londen, G J ^a,d   Perera, S ^b   Vujevich, K T ^a   Sereika, S M ^b   Bhattacharya, R ^c   Greenspan, S L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Breast cancer; Chemotherapy; Hip structural analysis; Osteoporosis; Risedronate

Indexed keywords

ANTINEOPLASTIC AGENT; PLACEBO; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID;

ADULT; ARTICLE; BONE STRENGTH; BONE STRUCTURE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED MENOPASE; CHEMOTHERAPY INDUCED MENOPAUSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FRAGILITY FRACTURE; HIP; HUMAN; MENOPAUSE; MENOPAUSE RELATED DISORDER; MUSCULOSKELETAL SYSTEM PARAMETERS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BONE DENSITY; BREAST TUMOR; FEMUR; HISTOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PATIENT COMPLIANCE; POSTMENOPAUSE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; FEMUR; HIP JOINT; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; POSTMENOPAUSE; STATISTICS, NONPARAMETRIC;

EID: 52449102126     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.03.027     Document Type: Article

References (44)

1. American Cancer Society. Breast Cancer Facts and Figures, 2005-2006; December 28, 2006. Available at http://www.cancer.org/downloads/STT/CAFF2005BrF. pdf. Accessed.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
3. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. [see comment]. Lancet 2005;365:1687-717.
4. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.[see comment]. J Clin Oncol 1996;14:1718-29.
5. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997;43:183-90.
6. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. Drug Safety 2005;28:401-16.
7. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769-79.
8. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000;18:1570-93.
9. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-11.
10. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005;165:552-8.
11. Hirbe A, Morgan EA, Uluckan O, Weilbaecher K. Skeletal complications of breast cancer therapies. Clin Cancer Res 2006;12:6309s-14s.
12. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997;15:955-62.
13. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6.
14. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9.
15. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92.
16. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004;20:341-9.
17. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005;27:1-11.
18. Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB. Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy 2006;26:104-14.
19. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-61.
20. Greenspan SL, Bhattacharya RK, Sereika SM, Brufsky A, Vogel VG. Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007;92:131-6.
21. Beck TJ, Ruff CB, Scott Jr WW, Plato CC, Tobin JD, Quan CA. Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int 1992;50:24-9.
22. Beck TJ, Stone KL, Oreskovic TL, Hochberg MC, Nevitt MC, Genant HK, et al. Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures. J Bone and Miner Res 2001;16:2103-10.
23. Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res 2005;20:1525-32.
24. Dawson-Hughes BJP, Shipp C. Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr 1987;46:685-7.
25. Towers AL, Clay CA, Sereika SM, McIntosh I, Greenspan SL. Skeletal integrity in patients with nail patella syndrome. J Clin Endocrinol Metab 2005;90:1961-5.
26. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-81.
27. Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
28. Petit MA, Beck TJ, Lin HM, Bentley C, Legro RS, Lloyd T. Femoral bone structural geometry adapts to mechanical loading and is influenced by sex steroids: the Penn State Young Women's Health Study. Bone 2004;35:750-9.
29. Uusi-Rasi K, Sievanen H, Heinonen A, Beck TJ, Vuori I. Determinants of changes in bone mass and femoral neck structure, and physical performance after menopause: a 9-year follow-up of initially peri-menopausal women. Osteoporos Int 2005;16:616-22.
30. Uusi-Rasi K, Beck TJ, Sievanen H, Heinonen A, Vuori I. Associations of hormone replacement therapy with bone structure and physical performance among postmenopausal women. Bone 2003;32:704-10.
31. Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, et al. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 2006;17:575-86.
32. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005;36:948-58.
33. Khoo BC, Beck TJ, Qiao QH, Parakh P, Semanick L, Prince RL, et al. In vivo short-term precision of hip structure analysis variables in comparison with bone mineral density using paired dual-energy X-ray absorptiometry scans from multi-center clinical trials. Bone 2005;37:112-21.
34. Melton III LJ, Beck TJ, Amin S, Khosla S, Achenbach SJ, Oberg AL, et al. Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int 2005;16:460-7.
35. El-Kaissi S, Pasco JA, Henry MJ, Panahi S, Nicholson JG, Nicholson GC, et al. Femoral neck geometry and hip fracture risk: the Geelong osteoporosis study. Osteoporos Int 2005;16:1299-303.
36. Crabtree NJ, Kroger H, Martin A, Pols HA, Lorenc R, Nijs J, et al. Improving risk assessment: hip geometry, bone mineral distribution and bone strength in hip fracture cases and controls. The EPOS study. European Prospective Osteoporosis Study. Osteoporos Int 2002;13:48-54.
37. Ahlborg HG, Nguyen ND, Nguyen TV, Center JR, Eisman JA. Contribution of hip strength indices to hip fracture risk in elderly men and women. J Bone Miner Res 2005;20:1820-7.
38. Gnudi S, Ripamonti C, Lisi L, Fini M, Giardino R, Giavaresi G. Proximal femur geometry to detect and distinguish femoral neck fractures from trochanteric fractures in postmenopausal women. Osteoporos Int 2002;13:69-73.
39. Szulc P, Duboeuf F, Schott AM, Dargent-Molina P, Meunier PJ, Delmas PD. Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study. Osteoporos Int 2006;17:231-6.
40. Hillier TA, Rizzo JH, Pedula KL, Black D, Stone KL, Cauley JA, et al. SR Cummings predicting long term hip fracture risk with bone mineral density and hip structure in post-menopausal women: the Study of Osteoporotic Fractures (SOF). J Bone Miner Res 2003;1074(18):S21 Abstract.
41. Beck TJ, Looker AC, Ruff CB, Sievanen H, Wahner HW. Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data.[see comment]. J Bone Miner Res 2000;15:2297-304.
42. Lonning PE. Bone safety of aromatase inhibitors versus tamoxifen. Int J Gynecol Cancer 2006;16(Suppl 2):518-20.
43. Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, et al. NCCN Task Force Report: bone health and cancer care. J Natl Compr Canc Netw 2006;4(Suppl 2):S1-S20 quiz S21-2.
44. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006;24:5305-12.